PLGA Nanoparticles Decorated with Anti-HER2 Affibody for Targeted Delivery and Photoinduced Cell Death

Molecules. 2021 Jun 28;26(13):3955. doi: 10.3390/molecules26133955.

Abstract

The effect of enhanced permeability and retention is often not sufficient for highly effective cancer therapy with nanoparticles, and the development of active targeted drug delivery systems based on nanoparticles is probably the main direction of modern cancer medicine. To meet the challenge, we developed polymer PLGA nanoparticles loaded with fluorescent photosensitive xanthene dye, Rose Bengal, and decorated with HER2-recognizing artificial scaffold protein, affibody ZHER2:342. The obtained 170 nm PLGA nanoparticles possess both fluorescent and photosensitive properties. Namely, under irradiation with the green light of 540 nm nanoparticles, they produced reactive oxygen species leading to cancer cell death. The chemical conjugation of PLGA with anti-HER2 affibody resulted in the selective binding of nanoparticles only to HER2-overexpressing cancer cells. HER2 is a receptor tyrosine kinase that belongs to the EGFR/ERbB family and is overexpressed in 30% of breast cancers, thus serving as a clinically relevant oncomarker. However, the standard targeting molecules such as full-size antibodies possess serious drawbacks, such as high immunogenicity and the need for mammalian cell production. We believe that the developed affibody-decorated targeted photosensitive PLGA nanoparticles will provide new solutions for ongoing problems in cancer diagnostics and treatment, as well in cancer theranostics.

Keywords: HER2; PLGA; Rose Bengal; affibody; nanoparticles; reactive oxygen species; targeted delivery.

MeSH terms

  • A549 Cells
  • Animals
  • CHO Cells
  • Cell Death / drug effects
  • Cricetulus
  • Drug Delivery Systems*
  • Humans
  • Nanoparticles* / chemistry
  • Nanoparticles* / therapeutic use
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Polylactic Acid-Polyglycolic Acid Copolymer* / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer* / pharmacology
  • Receptor, ErbB-2 / metabolism*
  • Recombinant Fusion Proteins* / chemistry
  • Recombinant Fusion Proteins* / pharmacology

Substances

  • Recombinant Fusion Proteins
  • affibody (ZHER2-342)2
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • ERBB2 protein, human
  • Receptor, ErbB-2